Buscar resultados de ensayos clínicos
Multiple Sclerosis, Chronic Progressive - 25 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis Condición:
Fecha: 2010-08-30 Intervenciones: Biological: MIS416 MIS416 intravenously every week |
Completed |
Nombre del estudio: Sunphenon in Progressive Forms of Multiple Sclerosis Condición: Multiple Sclerosis Fecha: 2008-11-28 Intervenciones:
|
Recruiting |
Nombre del estudio: A LOW-COST VIRTUAL REALITY GAMING PLATFORM FOR NEUROREHABILITATION OF HEMIPARESIS Condición:
Fecha: 2017-03-23 Intervenciones: Behavioral: Gaming CI Therapy Intensive remote (via video game) therapy for upper extremity hemiparesis. |
Recruiting |
Nombre del estudio: Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis Condición: Primary Progressive Multiple Sclerosis Fecha: 2016-11-08 Intervenciones:
|
Recruiting |
Nombre del estudio: Hydroxychloroquine in Primary Progressive Multiple Sclerosis Condición: Multiple Sclerosis, Primary Progressive Fecha: 2016-09-20 Intervenciones: Drug: Hydroxychloroquine Orally administered Hydroxychloroquine |
Available |
Nombre del estudio: Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Condición: Multiple Sclerosis Fecha: 2016-06-16 Intervenciones: Drug: Ocrelizumab Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 d |
Recruiting |
Nombre del estudio: Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) Condición:
Fecha: 2016-02-18 Intervenciones:
|
Completed |
Nombre del estudio: Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Condición: Multiple Sclerosis Fecha: 2016-01-14 Intervenciones: Drug: BG00012 (DMF) (Tecfidera®.) Subjects will take DMF 120 mg BID for the first 4 weeks of treatm |
Active, not recruiting |
Nombre del estudio: A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo Condición: Primary Progressive Multiple Sclerosis Fecha: 2014-10-31 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Condición:
Fecha: 2014-10-03 Intervenciones:
|